Skip to main content

Table 3 Univariate analysis of potential prognostic factors associated with hepatitis in HBsAg-negative DLBCL patients

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Factor Without hepatitis [cases (%)] With hepatitis [cases (%)] P value
Total 144 21  
HBcAb    0.013
 – 101 (70.1) 9 (42.9)  
 + 43 (29.9) 12 (57.1)  
HBeAb    1.000
 – 131 (91.0) 19 (90.5)  
 + 13 (9.0) 2 (9.5)  
Age (years)    0.399
 ≤60 62 (43.1) 7 (33.3)  
 >60 82 (56.9) 14 (66.7)  
Sex    0.756
 Female 60 (41.7) 8 (38.1)  
 Male 84 (58.3) 13 (61.9)  
ECOG PS    0.500
 0–1 125 (86.8) 17 (81.0)  
 ≥2 19 (13.2) 4 (19.0)  
B symptoms    0.726
 − 108 (75.0) 15 (71.4)  
 + 36 (25.0) 6 (28.6)  
Ann Arbor stage    0.129
 I–II 73 (50.7) 7 (33.3)  
 III-IV 70 (48.6) 14 (66.7)  
Liver involvement    0.598
 − 136 (94.4) 21 (100)  
 + 8 (5.6) 0 (0)  
Spleen involvement    1.000
 − 131 (91.0) 19 (90.5)  
 + 13 (9.0) 2 (9.5)  
Involved extranodal sites    0.586
 <2 111 (77.1) 15 (71.4)  
 ≥2 33 (22.9) 6 (28.6)  
Bone marrow involvement    1.000
 − 134 (93.1) 20 (95.2)  
 + 10 (6.9) 1 (4.8)  
IPI score    0.180
 0–1 63 (43.8) 6 (28.6)  
 2–5 80 (55.8) 15 (71.4)  
ALT    0.013
 ≤40 U/L 128 (88.9) 14 (66.7)  
 >40 U/L 16 (11.1) 7 (33.3)  
AST    0.019
 ≤45 U/L 131 (91.0) 15 (71.4)  
 >45 U/L 13 (9.0) 6 (28.6)  
TB    0.696
 ≤20.5 μmol/L 129 (89.6) 20 (95.2)  
 >20.5 μmol/L 15 (10.4) 1 (4.8)  
LDH    0.728
 ≤245 U/mL 88 (61.1) 12 (57.1)  
 >245 U/mL 56 (38.9) 9 (42.9)  
  1. Footnotes as in Table 1.